timothy sykes logo
Tempus AI Stock Slides As $1.5B Personalis Bet Raises Stakes Thumbnail
G Google News

Tempus AI Stock Slides As $1.5B Personalis Bet Raises Stakes

ELLIS HOBBS•UPDATED AUG. 19, 2026, 9:18 AM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

Tempus AI Inc. stocks have been trading up by 14.27 percent after upbeat coverage of its AI-driven healthcare innovations.

Key Takeaways

  • Tempus AI is buying Personalis for about $1.5B, mainly in stock, to plug leading MRD cancer assays into its AI oncology platform and attack a roughly $20B MRD market.
  • The Personalis announcement knocked TEM shares down 4%–6.9% in premarket and same-day trading as traders weighed dilution and deal risk.
  • Needham flagged the roughly 15.5x 2027 EV/sales multiple as steep versus peers but defended it given Personalis’ MRD growth and Medicare reimbursement traction.
  • A shareholder-rights firm is reviewing whether Tempus AI’s prior Personalis stake created conflicts and pressured PSNL holders into an unfair price.
  • Tempus AI beat Q2 expectations, raised 2026 revenue guidance to about $1.6B, expanded gross margin to 64%, and turned profitable, even as TEM trades well below 2025 highs.

Candlestick Chart

Live Update At 09:18:23 EDT: On Wednesday, August 19, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 14.27%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Tempus AI, trading under the TEM ticker, is moving from pure “story stock” into real numbers. The latest quarter showed revenue of about $1.27B over the trailing period, with Q2 sales modestly above Wall Street expectations and full-year guidance bumped to roughly $1.6B. For an AI‑driven healthcare name, that kind of top-line scale matters.

The margin picture is what really jumps out. TEM’s gross margin sits near 73% on the trailing data and was cited at 64% in Q2, showing the core diagnostics and data platform can throw off strong unit economics. Net income flipped positive, with about $5.6M in profit in the most recent quarter, but return metrics remain negative, signaling the company is still early in harvesting its cost base.

More Breaking News

On the balance sheet, TEM holds roughly $816M in cash and short-term investments against about $259M in long-term debt and a current ratio around 3.3, giving it room to absorb large deals like Personalis. The stock, however, has been choppy. From late July to mid‑August, TEM ran from the low $40s to above $55 before pulling back to about $49, a classic momentum surge followed by profit-taking that active traders watch closely.

Why Traders Are Watching TEM After The Personalis Deal

Traders are glued to TEM because Tempus AI just made a $1.5B swing at Personalis to lock up more of the minimal residual disease (MRD) market. This is not a bolt‑on tweak. It’s a statement that Tempus wants to own the full cancer journey: diagnosis, treatment selection, and recurrence monitoring, all plugged into its AI engine.

The deal adds tumor‑informed MRD assays from Personalis directly into the Tempus AI platform. Management is clearly targeting a roughly $20B MRD opportunity, using TEM’s massive clinical data asset — tens of millions of patients and hundreds of petabytes — as the backbone. When you combine that data scale with high‑value MRD tests, you get more training data, better AI models, and, in theory, stickier pharma and provider relationships.

The market’s first reaction, though, was textbook “sell the news.” On announcement, TEM shares dropped about 4%–6.9% as traders digested dilution, execution risk, and the price tag. At $16.25 per Personalis share, or about a $1.5B enterprise value, Tempus is paying roughly 15.5x estimated 2027 EV/sales. That’s rich versus other small‑ and mid‑cap growth names.

Needham pushed back on the sticker shock, arguing the multiple is justified by Personalis’ NeXT Personal MRD platform and recent Medicare reimbursement wins, and noting limited antitrust risk given both companies’ modest market share. Still, headline risk hangs over TEM: a shareholder‑rights firm is reviewing whether Tempus AI’s existing stake and strategic partnership with Personalis created conflicts that shortchanged PSNL holders. For traders, this adds a legal overhang that can flare up in the tape even if the strategic logic stands.

Conclusion

Tempus AI now sits at an interesting crossroads. On one hand, TEM just delivered what many story‑driven growth names never do: real execution. Q2 revenue came in ahead of expectations, full‑year guidance was raised to around $1.6B, gross margin expanded into the mid‑60s, and the company posted positive net income. That shows the AI‑plus‑genomics model is not just hype.

On the other hand, the Personalis acquisition raises the stakes. TEM is using its balance sheet and stock to buy a premium MRD asset at a hefty multiple, in a deal that initially knocked the share price and attracted legal scrutiny focused on Personalis’ side of the table. Traders now have to weigh long‑term MRD and AI upside against near‑term dilution, integration risk, and headline noise.

The chart reflects that tension. TEM ripped from the low $40s to the mid‑$50s, then faded back under $50 as the dust settled — classic volatility around big news. For active traders, this is where discipline matters. As Tim Sykes loves to remind his community, “The market rewards prepared traders who cut losses quickly and never fall in love with a story.” As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. For TEM, the story around AI, data, and cancer care is powerful, but the only way to trade it is to respect the levels, watch the volume, and let the price action confirm or reject the thesis. This article is for educational and research purposes only.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”